Advancing state-of-the-art precision medicine
to dramatically improve the lives of people with cancer
Precision for Patients
Xerna™ RNA-based Platform
Novel, Targeted Clinical Programs
Ushering in a new era of precision medicine
OncXerna Therapeutics is aiming to deliver next-generation precision medicine to a larger group of cancer patients by leveraging the company’s Xerna™️ RNA-based biomarker platform to prospectively identify patients based on the dominant biology of their cancer. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes.
News and Events
OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma
Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular cancer patients Data reinforce the potential of Xerna TME Panel to substantially improve outcomes for patients Waltham MA, January 23, 2023, OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA expression-based biomarker platform to predict patient responses […]